Selank is a synthetic Russian peptide built from tuftsin, an endogenous immune peptide, with the same Pro-Gly-Pro stabilizing tail used in Semax. It is registered in Russia as a prescription nootropic and anxiolytic nasal-drop drug. A search for this entry combining Selank with human and clinical trial terms returned no results at all; every anxiolytic, cognitive, immune and sleep finding located was measured in rats or mice, not in people, which makes Selank’s evidence base look like a preclinical drug’s despite it being sold as an approved medicine in Russia.
Ask about Selank
Research snapshot
| Peptide category | Synthetic heptapeptide, extended tuftsin analogue (shares the Pro-Gly-Pro tail used in Semax) |
| Primary research interest | Anxiolytic and nootropic effects; also studied for reducing withdrawal severity and substance-related memory disturbance |
| Highest available evidence | Published animal (rat/mouse) research only, no human trial was located in the searches run for this entry |
| Human research available | No: a search combining Selank/TP-7 with human and clinical trial terms returned no results, despite its Russian drug registration |
| Development status | Long-registered Russian prescription drug; evidence base outside Russia reads as preclinical |
| Regulatory status | Registered as a prescription drug in Russia only; not approved by the FDA, EMA, or any other major regulator |
Technical identity
| Primary name | Selank |
| Alternative names | TP-7 (older pharmacology literature); “tuftsin analogue” |
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Amino-acid length | 7 residues |
| Molecular formula | Not independently re-verified in this research pass |
| Molecular weight | Not independently re-verified in this research pass |
| CAS Registry Number | Not independently re-verified in this research pass |
| PubChem CID | Not independently re-verified in this research pass |
| UNII | Not established |
| DrugBank ID | Not established |
| Chemical modifications | Tuftsin sequence (Thr-Lys-Pro-Arg) extended with a Pro-Gly-Pro stabilizing tripeptide tail |
| Peptide class | Tuftsin-derived heptapeptide |
| Primary biological target | Not conclusively established: proposed immune and GABAergic/monoamine modulation inherited from the tuftsin backbone |
| Developer or originator | Russian pharmacology research program (same lineage as Semax) |
| Development status | Registered prescription drug in Russia; no FDA/EMA development pathway |
What it is
Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, built by extending the endogenous immunomodulator tuftsin (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro tripeptide used to build Semax from ACTH(4-7). It carries the laboratory designation TP-7 in the older pharmacology literature. Like Semax, it was developed in Russia and is registered there as a prescription nootropic and anxiolytic drug sold as intranasal drops. It has no FDA label, no EMA authorisation and no approval in any jurisdiction outside Russia.
Potential benefits and research applications
Anxiolytic (anti-anxiety) effect, the drug’s registered use in Russia, tested only in rats in this search
Selank is registered and marketed in Russia as an anxiolytic. Published pharmacology work reports reduced anxiety-like behavior in rat fear and anxiety models sustained over several weeks of dosing, and this is the effect the Russian registration is presumably built on.
Evidence: has been reported in animal research only (Tier 3, published animal evidence); no human anxiolytic trial was located for this entry, despite the drug’s human regulatory approval in Russia.
Reducing withdrawal severity and substance-related memory disturbance, demonstrated in rat models of morphine and alcohol exposure
A 2022 rat study found Selank reduced the total index of naloxone-precipitated morphine withdrawal, and a 2019 rat study found it prevented ethanol-induced memory and BDNF disturbances after chronic alcohol exposure. Both are specific, real, and both are animal findings.
Evidence: has been shown in rat models (Tier 3, published animal evidence); has not been established in any human population.
Immune modulation and general nootropic support, the broadest and least-substantiated claims
Selank’s tuftsin backbone is an endogenous immune signaling peptide, which is cited as the basis for immune-modulating and general cognitive-support claims made for the compound in consumer material. Supporting data located for this entry is limited to gene-expression changes in mouse spleen and general rodent behavioral testing.
Evidence: is being investigated at the laboratory/mechanistic level (Tier 4); has not been established in human immune or cognitive outcomes.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Human research | Not applicable | No established or reliably sourced human dosing information was identified | Not applicable | Not applicable | No human trial was located in this search |
| Anxiolytic / withdrawal reduction (rat models) | Injection (IP) | 0.3 mg/kg, most commonly cited | Single dose or daily, study-dependent | Up to 4 weeks in the anxiety-model literature | Published animal research |
| Anxiolytic/nootropic use, general (community) | Intranasal | Commonly reported as 250 mcg to 3 mg per dose | One to three times daily | Often cycled, days to a few weeks | Community / vendor reported: no published human dose exists to check this figure against |
The human trial record: there is not one, in this search
This is the central fact of this entry, and it runs against the assumption a reader might carry from Semax’s own page. A PubMed search combining Selank or TP-7 with human, clinical trial and anxiety terms returned no results. Every study located for this entry that actually administered Selank or TP-7 to a living animal did so in rats, not in people.
Those rat studies are real and specific. A 2022 study found that a single 0.3 mg/kg injection of Selank reduced the total index of naloxone-precipitated morphine withdrawal in rats by 39.6 percent, close to but somewhat below diazepam’s 49.3 percent at 2 mg/kg. A 2019 study found that the same 0.3 mg/kg dose, given over 7 days, prevented ethanol-induced memory and BDNF disturbances in rats chronically exposed to alcohol. Older Russian-language work from the 1990s and 2000s reported anxiolytic effects of TP-7 in rat anxiety-fear models sustained over four weeks, along with effects on gene expression for chemokines and cytokines in mouse spleen.
None of that is a human finding. Selank is sold to and used by people in Russia as a registered drug, and it is plausible that Russian regulatory submissions relied on human data not indexed in the international literature searched here. But on the specific search run for this entry, the published, findable human evidence for Selank’s anxiolytic, cognitive, mood, immune, sleep and anti-inflammatory claims is exactly what a preclinical drug’s evidence base looks like: entirely rodent.
What is not known
Whether any of the anxiolytic, mood, cognitive, immune-modulating, sleep or neuroprotective effects reported in rats and mice reproduce in a human being at any dose, by any route. No human trial was located in this search.
Whether Russian regulatory approval for Selank rests on human data that exists but was not indexed or was not located by the searches run for this entry. That possibility is noted rather than resolved.
Human pharmacokinetics, human safety at any duration, and drug interactions. No such human data was located.
Frequently asked questions
What is Selank?
Selank is a synthetic heptapeptide built from tuftsin, an endogenous immune peptide, with a Pro-Gly-Pro tail added for stability. It is registered in Russia as a prescription anxiolytic and nootropic nasal-drop drug.
How does Selank work?
It is proposed to act through modulation of the immune and GABAergic/monoamine systems inherited from its tuftsin backbone, though the exact human mechanism is not established because no human trial was located for this entry.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified. Every dose figure located for this entry comes from rat studies, most often 0.3 mg/kg by injection.
What dosage commonly circulates online?
Community material typically describes 250 micrograms to 3 milligrams intranasally, one to three times daily. This figure has no published human study to check it against.
Has Selank been studied in humans?
A search combining Selank or its older designation TP-7 with human and clinical trial terms returned no results for this entry. It is possible Russian regulatory filings rely on unindexed human data, but no such data was located.
Is Selank approved for use?
It is registered as a prescription drug in Russia only, with no FDA, EMA or other major regulatory approval elsewhere.
What routes of administration are reported?
Intranasal administration is the route used in Russian registration and in essentially all community-reported use; published animal studies used injection.
Does Selank reduce anxiety?
It has been shown to reduce anxiety-like behavior in rat models. Whether this translates to a human anxiolytic effect has not been established by any trial located for this entry.
What side effects have been reported?
No human safety or adverse-event data was located for this entry. Rat studies did not report a detailed toxicology profile at the doses tested.
What remains unknown about Selank?
Whether any of its anxiolytic, cognitive, immune or sleep effects in rats and mice reproduce in a human being at any dose; whether Russian approval rests on unindexed human data; and its human pharmacokinetics and safety profile, none of which were located for this entry.
Bottom line
Selank is a real, registered Russian drug with a genuinely unusual evidence gap: a search combining it with human and clinical trial terms returned nothing, so every anxiolytic, withdrawal-reducing and immune-modulating finding documented for this entry comes from rats or mice, not people. That does not mean the drug does not work in humans, since Russian approval may rest on data not indexed in the literature searched here, but it does mean the confident anxiolytic and nootropic claims made for Selank online are running well ahead of any published human evidence this entry could locate.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Anxiolytic/nootropic use, general | Intranasal | 250 to 3,000 mcg per dose | One to three times daily | Often cycled, days to a few weeks |
Circulating figures for Selank describe intranasal doses ranging roughly from 250 micrograms to 3 milligrams per administration. There is no published human dose to check that figure against, favourably or unfavourably, because no human trial was located for this compound in this search. The rat dose most often used in the published pharmacology literature, 0.3 mg/kg, would scale to roughly 24 milligrams for an 80 kg adult using a simple linear conversion, a figure well above anything described in circulating human-use material; but that conversion is presented here only to illustrate the size of the gap, not as a basis for a human dose, since simple linear scaling from rat to human is not how pharmacokinetics actually works and this compound has no human PK data to correct it with.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Konstantinopolsky MA, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med 2022;173(6):730-733. Rat, 0.3 mg/kg IP. PMID 36322304
- Kolik LG, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med 2019;167(5):641-644. Rat, 0.3 mg/kg IP, 7 days. PMID 31625062
- Czabak-Garbacz R, et al. Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight. Pharmacol Rep 2006;58(4):562-567. Rat, 0.3 mg/kg IP daily, 4 weeks. PMID 16963804
Compare Selank with related compounds
Research area: Neuro and cognitive.